Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603213 | 0.87 | MEN1 (0.77) | MEN1KMT2AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6603317 | 0.87 | MEN1 (0.77) | MEN1KMT2AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6603205 | 0.87 | MEN1 (0.77) | MEN1KMT2AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6603319 | 0.87 | MEN1 (0.77) | MEN1KMT2AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6603409 | 0.87 | KMT2A (0.77) | MEN1KMT2ATP53POLBLMNA | |
| SCHEMBL6603407 | 0.87 | KMT2A (0.77) | MEN1KMT2ATP53POLBLMNA | |
| SCHEMBL7509334 | 0.86 | MEN1 (0.76) | MEN1KMT2AMAPTTP53SMN1; SMN2 | |
| SCHEMBL7509330 | 0.86 | MEN1 (0.76) | MEN1KMT2AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6605747 | 0.86 | MEN1 (0.75) | MEN1KMT2AMAPTTP53POLB | |
| SCHEMBL6605741 | 0.86 | MEN1 (0.75) | MEN1KMT2AMAPTTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210087199-A1 | Synthetic Method for Benzimidazo[1,2-c]quinazolin-6-ones | JIANGNAN UNIVERSITY (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3453393-B1 | NOVEL QUINAZOLINONE DERIVATIVES INHIBITING PI3K AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | BIOWAY INC (KR) | 2020-09-09 | — | — | EP | disclosed |
| CN-109475559-B | Quinazolinone derivatives inhibiting PI3K and pharmaceutical compositions containing the same | (株式会社)生命程道 | 2020-06-23 | — | — | CN | disclosed |
| US-20200148684-A1 | Substituted Quinazolinones For Inhibiting PI3K | BIOWAY., INC (KR) | 2020-05-14 | — | — | US | disclosed |
| US-10577369-B2 | Substituted quinazolinones for inhibiting PI3K | BIOWAY., INC (KR) | 2020-03-03 | — | — | US | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | MEN1 410/4885KMT2A 4460/4885MAPT 1721/4885 |
| US-20200148684-A1 | Substituted Quinazolinones For Inhibiting PI3K | PIK3CD, PIK3R5, PIK3CG | MEN1 2737/4885KMT2A 1934/4885MAPT 4616/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | MEN1 853/4885KMT2A 4761/4885MAPT 1657/4885 |
| US-10577369-B2 | Substituted quinazolinones for inhibiting PI3K | PIK3CD, PIK3R5, PIK3C2B | MEN1 1890/4885KMT2A 2152/4885MAPT 4834/4885 |
| US-20210087199-A1 | Synthetic Method for Benzimidazo[1,2-c]quinazolin-6-ones | PKM, PDK2, PDK1 | MEN1 3325/4885KMT2A 408/4885MAPT 4144/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | MEN1 671/4885KMT2A 4411/4885MAPT 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.